Recurrent Hyperbilirubinemia with Midostaurin during Consolidation in a Patient of AML with FLT3 Mutation and Review of Literature for Alternative Maintenance Strategy

Recurrent Hyperbilirubinemia with Midostaurin during Consolidation in a Patient of AML with FLT3 Mutation and Review of Literature for Alternative Maintenance Strategy

Saved in:

Bibliographic Details
Main Authors:	Deepak Kumar Shukla, Satyendra Katewa, Ravikant Porwal
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2025-08-01
Series:	Indian Journal of Medical and Paediatric Oncology
Subjects:	AML FLT3 mutation midostaurin hyperbilirubinemia sorafenib
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-1772255
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

FLT3: A narrative review
by: Nikhil M Kumar, et al.
Published: (2025-01-01)

FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context
by: Suvir Singh, et al.
Published: (2024-04-01)

Targeted therapy of newly diagnosed <i>FLT3</i>-mutated acute myeloid leukemia. A single-center ambispective cohort study
by: N. K. Pastukhov, et al.
Published: (2025-03-01)

LOW DOSE CYTARABINE PLUS SORAFENIB IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA
by: Tural Mahmudov
Published: (2025-07-01)

A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice
by: Monica Messina, et al.
Published: (2024-12-01)

FREQUENCY OF FMS-LIKE TYROSINE KINASE 3 KINASE DOMAIN POINT MUTATION (FLT3/TKD MUTATION) IN DIFFERENT AGE GROUPS OF ACUTE MYELOID LEUKEMIA PATIENTS.
by: Khaleeq unnisa, et al.
Published: (2014-08-01)

TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT
by: Cristina Papayannidis, et al.
Published: (2022-10-01)

Clinical and Biological Characteristics of Four Patients with Aggressive Systemic Mastocytosis Treated with Midostaurin
by: Delia Soare, et al.
Published: (2025-07-01)

Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature
by: Jayastu Senapati, et al.
Published: (2014-02-01)

Gilteritinib
by: Harini Raghunathan, et al.

FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers
by: Yongchang Tang, et al.
Published: (2025-01-01)

A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML
by: Noor Rashidha Binte Meera Sahib, et al.
Published: (2024-11-01)

The Novel Diketopiperazine Derivative, Compound 5-3, Selectively Inhibited the Proliferation of FLT3-ITD Mutant Acute Myeloid Leukemia (AML) Cells
by: Shijie Bi, et al.
Published: (2025-07-01)

Characterization of the FLT3 Mutation in Newly Diagnosed Patients with Acute Myeloid Leukemia
by: Luay Fahad, et al.
Published: (2024-06-01)

Decursin induces FLT3-ITD acute myeloid leukemia cell apoptosis by increasing the expression of the ubiquitin-conjugase UBE2L6
by: Tianxin Zhang, et al.
Published: (2025-04-01)

Targeting protein kinase C-α prolongs survival and restores liver function in sepsis: Evidence from preclinical models
by: Ling Xiong, et al.
Published: (2025-02-01)

Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia
by: Tessa S. Seale, et al.
Published: (2025-05-01)

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation
by: Zhonghui Jiang, et al.
Published: (2025-08-01)

Effective treatment with Gilteritinib-based regimens for FLT3-mutant extramedullary relapse in acute promyelocytic leukemia
by: Chun-xiao Hou, et al.
Published: (2024-12-01)

Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations
by: Jie Yang, et al.
Published: (2025-09-01)

Feasible and Rapid Screening of <i>IDH1/2</i> and <i>FLT3-TKD2</i> Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia
by: José Vicente Gil, et al.
Published: (2025-05-01)

Efficacy of Orlistat on Hyperbilirubinemia in Full Term Neonates
by: M Habibi, et al.
Published: (2024-03-01)

The association of FAT1 mutations with therapeutic outcomes in AML, especially in receiving venetoclax combination
by: Tao Wang, et al.
Published: (2025-03-01)

CEBPA mutation in acute myeloid leukemia: prognostic impact of bZIP domain mutation
by: Roy Raj, et al.
Published: (2024-10-01)

Gilteritinib maintenance after allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute myeloid leukemia with FLT3-internal tandem duplication mutation
by: Chen Liang, et al.
Published: (2025-12-01)

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
by: Frank G. Rücker, et al.
Published: (2024-12-01)

Model to Predict Hyperbilirubinemia in Healthy Term and Near-Term Newborns with Exclusive Breast Feeding
by: Hsin-Chung Huang, et al.
Published: (2012-12-01)

NURSING CARE OF NEONATAL JAUNDICE IN HYPERBILIRUBINEMIA BABIES: A CASE REPORT
by: Anestasia Pangestu Mei Tyas, et al.
Published: (2021-10-01)

Risk Factor Analysis for Late-onset Neonatal Hyperbilirubinemia in Taiwanese Infants
by: Mi-Shu Huang, et al.
Published: (2009-12-01)

Молекулярная диагностика мутаций гена FLT3 у пациентов с острыми миелоидными лейкозами
by: Е. К. Зайкова, et al.
Published: (2020-04-01)

Eosinophil count in blood with neonatal hyperbilirubinemia treated with phototherapy
by: Yusra Zaher Salman, et al.
Published: (2024-11-01)

Weight Loss Percentage Prediction of Subsequent Neonatal Hyperbilirubinemia in Exclusively Breastfed Neonates
by: Rui-Jane Chang, et al.
Published: (2012-02-01)

Peripheral blood biomarkers as differential diagnostic markers of disease severity in neonates with hyperbilirubinemia
by: Dereje Mengesha Berta, et al.
Published: (2025-01-01)

Outcomes of neonatal hyperbilirubinemia and associated factors at a tertiary hospital in Ghana
by: Naana Ayiwa Wireko Brobby, et al.
Published: (2025-04-01)

Development and preclinical characterization of AMG 329: a human antibody neutralizing FLT3 ligand
by: Annie Lau-Kilby, et al.
Published: (2025-12-01)

SPECTRUM AND IMMUNOPHENOTYPIC PROFILE OF ACUTE LEUKEMIA: A TERTIARY CENTER FLOW CYTOMETRY EXPERIENCE
by: Nishit Gupta, et al.
Published: (2019-02-01)

A study of cord blood alkaline phosphatase as a predictor of neonatal hyperbilirubinemia in a tertiary hospital
by: Vijay Baburao Sonawane, et al.
Published: (2025-01-01)

Investigation of the relationship between cord clamping time and risk of hyperbilirubinemia
by: Yüksel Yaşartekin, et al.
Published: (2020-10-01)

Clinical predictive score of predischarge screening for severe hyperbilirubinemia in late preterm and term infants
by: Pichaya Thanomsingh
Published: (2020-08-01)

Hematological parameter changes and associated factors in neonates with hyperbilirubinemia treated with phototherapy
by: Adamu Kassie, et al.
Published: (2025-02-01)